SCHEMBL25845423

SCHEMBL25845423

Nc1ccc(N2CCC(CCC3CCCCC3)CC2)c(F)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.51
MAPT P10636 4/20 0.51
LMNA P02545 1/20 0.51
MAPK1 P28482 1/20 0.51
GFER P55789 1/20 0.51
TDP1 Q9NUW8 1/20 0.51
POLB P06746 1/20 0.43
HTT P42858 3/20 0.42
NFE2L2 Q16236 1/20 0.40
GAA P10253 4/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
THRB P10828 1/20 0.39
NR4A1 P22736 1/20 0.39
PTK2B Q14289 1/20 0.39
ACHE P22303 1/20 0.38
HTR4 Q13639 1/20 0.38
HPGD P15428 3/20 0.38
TSHR P16473 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25845549 0.84 ALDH1A1 (0.55) ALDH1A1MAPTLMNAMAPK1GFER
SCHEMBL23823282 0.83 ALDH1A1 (0.49) ALDH1A1MAPTLMNAMAPK1GFER
SCHEMBL29890862 0.82 MAPT (0.54) ALDH1A1MAPTLMNAMAPK1GFER
SCHEMBL20231853 0.82 MAPT (0.54) ALDH1A1MAPTLMNAMAPK1GFER
SCHEMBL17264125 0.80 MAPT (0.61) ALDH1A1MAPTLMNAMAPK1GFER
SCHEMBL157935 0.80 ALDH1A1 (0.65) ALDH1A1MAPTLMNAMAPK1GFER
SCHEMBL4918379 0.80 ALDH1A1 (0.65) ALDH1A1MAPTLMNAMAPK1GFER
SCHEMBL30721891 0.80 ALDH1A1 (0.65) ALDH1A1MAPTLMNAMAPK1GFER
SCHEMBL31216628 0.79 ALDH1A1 (0.45) ALDH1A1MAPTLMNAMAPK1GFER
SCHEMBL12074106 0.79 ALDH1A1 (0.59) ALDH1A1MAPTLMNAMAPK1GFER

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11691972-B2 Compounds for targeted degradation of BRD9 C4 THERAPEUTICS, INC. (US) 2023-07-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11691972-B2 Compounds for targeted degradation of BRD9 BRD9, BRD1, BRWD1 ALDH1A1 4230/4885MAPT 1277/4885LMNA 2718/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.